(INNS)
VEPSITAMAB(INND)
VEPSITAMAB(INNC)
IMMUNOGLOBULIN SCFV-SCFV-SCFC, ANTI-[HOMO SAPIENS MUC17 (MUCIN 17, CELL SURFACE ASSOCIATED)] AND ANTI- [HOMO SAPIENS CD3E (CD3E, CD3 EPSILON)], MONOCLONAL ANTIBODY SINGLE CHAIN, BISPECIFIC; IG SINGLE CHAIN SCFV-SCFV-SCFC, ANTI-MUC17 AND ANTI- CD3E (1-984) [SCFV-VH-V-LAMBDA ANTI-MUC17 (1- 242) [VH (HOMO SAPIENS IGHV4-34*01 (91.8%) - (IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.7.14] (26- 33.51-57.96-109)) (1-120) -15-MER TRIS(TETRAGLYCYLSERYL) LINKER (121-135) -V-LAMBDA (HOMO SAPIENS IGLV3-1*01 (93.7%) -IGLJ2*01 (90.9%) G120>C (234), CDR-IMGT [6.3.9] (161-166.184-186.223-231)) (136-242)] -5-MER TETRAGLYCYL-SERYL LINKER (243-247) - [SCFV-VH-V-LAMBDA ANTI-CD3E (248-496) [VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV10-1*02...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
VEPSITAMABUM(INN)